Heather Giles

MRC Centre for Regenerative Medicine — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index2.1kcitations60works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(17), Inflammatory mediators and NSAID effects(11), Synthesis and Characterization of Heterocyclic Compounds(6), Nitric Oxide and Endothelin Effects(4), Synthesis and biological activity(4)

Publications60 total

Astrocytes control motor neuronal axonal transport deficits in C9ORF72 ALS
2024
The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): overview and results of the research prioritisation survey process
BMJ Open·2014· 52 citedOpen Access
For the love of paradox
Behavioural Pharmacology·2011· 12 cited
Reviewer comments on <i>Reflections on drug research</i> by Sir James Black
British Journal of Pharmacology·2010Open Access
GW627368X ((<i>N</i>‐{2‐[4‐(4,9‐diethoxy‐1‐oxo‐1,3‐dihydro‐2<i>H</i>‐benzo[<i>f</i>]isoindol‐2‐yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP<sub>4</sub> receptor antagonist
British Journal of Pharmacology·2006· 78 citedOpen Access
Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP<sub>4</sub>, EP<sub>2</sub>, DP and IP receptor subtypes
British Journal of Pharmacology·2005· 26 citedOpen Access
Functional pharmacology of human prostanoid EP2 and EP4 receptors
European Journal of Pharmacology·2004· 60 cited
Effects of acute and chronic administration of β-adrenoceptor ligands on airway function in a murine model of asthma
Proceedings of the National Academy of Sciences·2004· 145 citedOpen Access
Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary artery
British Journal of Pharmacology·2003· 12 citedOpen Access
Effects of chronic treatment with beta-adrenoceptor antagonist and inverse agonists on a murine model of asthma
The FASEB Journal·2003
Spontaneous contractions of myometrium from humans, non‐human primate and rodents are sensitive to selective oxytocin receptor antagonism <b><i>in vitro</i></b>
BJOG An International Journal of Obstetrics & Gynaecology·2001· 29 cited
Spontaneous contractions of myometrium from humans, non-human primate and rodents are sensitive to selective oxytocin receptor antagonism in vitro
British Journal of Obstetrics and Gynaecology·2001· 16 cited
Discovery of 4-[3-(<i>trans</i>-3-Dimethylaminocyclobutyl)-1<i>H</i>-indol-5-ylmethyl]- (4<i>S</i>)-oxazolidin-2-one (4991W93), a 5HT<sub>1B/1D</sub>Receptor Partial Agonist and a Potent Inhibitor of Electrically Induced Plasma Extravasation
Journal of Medicinal Chemistry·2001· 41 citedOpen Access
Use of a Dual Firefly and Renilla Luciferase Reporter Gene Assay to Simultaneously Determine Drug Selectivity at Human Corticotrophin Releasing Hormone 1 and 2 Receptors
Analytical Biochemistry·2000· 25 cited
Pharmacological characterization of human recombinant melatonin mt<sub>1</sub> and MT<sub>2</sub> receptors
British Journal of Pharmacology·2000· 132 citedOpen Access
Receptor dimerization and Hill coefficients
Trends in Pharmacological Sciences·1999
Signalling by CXC‐chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPγS binding induced by IL‐8 and GRO<i>α</i>
British Journal of Pharmacology·1999· 74 citedOpen Access
Pharmacological characterisation of melatonin mt1 receptor-mediated stimulation of [35S]-GTPγs binding∗∗The nomenclature and classification of melatonin receptors used here was recently approved by the Nomenclature Committee of the International Union of Pharmacology [1]. The denomination ‘mt1’ corresponds to that of the recombinant receptor previously termed Mel1a. MT2 refers to native functional receptors with pharmacological characteristics similar to that of the recombinant receptor mt2, previously termed Mel1b. MT3 corresponds to the pharmacologically defined melatonin receptor subtype, with unknown molecular structure, previously referred to as ML2.
Biochemical Pharmacology·1998· 5 cited
Pharmacological characterisation of -melatonin binding to human recombinant melatonin Mel-1A and Mel-1B receptors
1997
Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT<sub>1B/1D</sub> receptor partial agonist, 311C90 (zolmitriptan)
British Journal of Pharmacology·1997· 101 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Graeme R. Martin(8), Paul Barraclough(7), D. Cambridge(7), V.P. Gerskowitch(6), Mary L. Bolofo(5), Peter Randall(5), Lawrence D. Colebrook(5), P. Leff(4), J.W. Black(4), David Firmin(4), W. R. KING(4), Gita P. Shah(4), Michael Kelly(3), Alan D. Robertson(3), Richard A. Bond(3), I.J.M. Beresford(3), Richard J. Wilson(3), Sharron A. Rhodes(3), David W. Gray(3), Robert C. Glen(3)